A detailed history of Royal Bank Of Canada transactions in Ocugen, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 32,936 shares of OCGN stock, worth $25,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,936
Previous 25,735 27.98%
Holding current value
$25,360
Previous $39,000 17.95%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.98 - $1.95 $7,056 - $14,041
7,201 Added 27.98%
32,936 $32,000
Q2 2024

Aug 14, 2024

BUY
$1.18 - $1.98 $20,533 - $34,453
17,401 Added 208.8%
25,735 $39,000
Q1 2024

Nov 05, 2024

SELL
$0.5 - $1.83 $8,700 - $31,843
-17,401 Reduced 67.62%
8,334 $13,000
Q1 2024

May 15, 2024

BUY
$0.5 - $1.83 $3,078 - $11,265
6,156 Added 282.64%
8,334 $13,000
Q4 2023

Feb 14, 2024

BUY
$0.36 - $0.57 $39 - $62
110 Added 5.32%
2,178 $1,000
Q3 2023

Nov 14, 2023

BUY
$0.4 - $0.62 $72 - $111
180 Added 9.53%
2,068 $0
Q2 2023

Aug 14, 2023

SELL
$0.45 - $0.88 $5,379 - $10,520
-11,955 Reduced 86.36%
1,888 $1,000
Q1 2023

May 15, 2023

SELL
$0.82 - $1.33 $17,846 - $28,946
-21,764 Reduced 61.12%
13,843 $11,000
Q4 2022

Feb 14, 2023

BUY
$1.11 - $1.87 $34,191 - $57,601
30,803 Added 641.19%
35,607 $46,000
Q3 2022

Nov 14, 2022

BUY
$1.75 - $3.1 $2,457 - $4,352
1,404 Added 41.29%
4,804 $8,000
Q2 2022

Aug 15, 2022

SELL
$1.83 - $3.45 $14,683 - $27,682
-8,024 Reduced 70.24%
3,400 $8,000
Q1 2022

May 16, 2022

SELL
$2.34 - $4.72 $80,481 - $162,339
-34,394 Reduced 75.07%
11,424 $37,000
Q4 2021

Feb 14, 2022

BUY
$4.38 - $15.67 $98,484 - $352,339
22,485 Added 96.37%
45,818 $209,000
Q3 2021

Nov 15, 2021

BUY
$6.36 - $8.51 $60,496 - $80,947
9,512 Added 68.82%
23,333 $168,000
Q2 2021

Aug 16, 2021

BUY
$5.52 - $15.68 $76,291 - $216,713
13,821 New
13,821 $111,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $167M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.